Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.

ABSTRACT:

Introduction

People living with HIV (PLHIV) have an elevated risk of atherosclerotic cardiovascular disease (CVD) compared to their HIV-negative peers. Expanding statin use may help alleviate this burden. However, the choice of statin in the context of antiretroviral therapy is challenging. Pravastatin and pitavastatin improve cholesterol levels in PLHIV without interacting substantially with antiretroviral therapy. They are also more expensive than most statins. We evaluated the cost-effectiveness of pravastatin and pitavastatin for the primary prevention of CVD among PLHIV in Thailand who are not currently using lipid-lowering therapy.

Methods

We developed a discrete-state microsimulation model that randomly selected (with replacement) individuals from the TREAT Asia HIV O

SUBMITTER: Boettiger DC 

PROVIDER: S-EPMC7305414 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature